Research programme: noble-gas therapeutics- Nobilis therapeutics

Drug Profile

Research programme: noble-gas therapeutics- Nobilis therapeutics

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator McLean Hospital
  • Developer McLean Hospital; Nobilis Therapeutics
  • Class Elements
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Panic disorder
  • Preclinical Post-traumatic stress disorders

Most Recent Events

  • 28 Mar 2016 Nobilis therapeutics plans a phase I trial for Post-traumatic stress disorder in USA (9193288; CTP 270037)
  • 28 Mar 2016 Noble gas containing mixtures licensed to Nobilis therapeutics for the treatment of Post-traumatic stress disorder
  • 11 Feb 2013 Phase-I clinical trials in Post-traumatic stress disorder in Russia (Inhalation) (ISRCTN15184285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top